Ozempic 1.34 mg/ml (1 mg/dose) Solution for injection in pre-filled pen

Manufacturer

Ozempic is manufactured by Novo Nordisk.

Contents

Each pre-filled pen contains 4 mg of semaglutide in a solution of 3.0 mL. Each dose comprises 1 mg of semaglutide in 0.74 mL of solution. Semaglutide is a human glucagon-like peptide-1 (GLP-1) analogue produced in Saccharomyces cerevisiae cells by recombinant DNA technology.

Indication

Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. It is also used to reduce the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, non-fatal myocardial infarction, and non-fatal stroke in adults with type 2 diabetes who have established CV disease or are at high risk for CV disease

Drug Interactions

Ozempic can interact with other medications, including:

• Insulin: Your doctor may need to adjust the dose of insulin and recommend monitoring blood sugar levels more frequently to avoid hyperglycaemia and diabetic ketoacidosis.

• Sulfonylureas: A reduction in the dose of sulfonylureas may be necessary to reduce the risk of hypoglycaemia.

• Oral anticoagulants: Frequent blood tests may be needed to check how quickly your blood clots